Liu Chao, Liu Yi Ran, Chen Jian, Zhuo Shao Yang, Dalin Martin, Liu Shao Hua, Wei Feng Cai
Department of Oral and Maxillofacial Surgery and Institute of Dental Medicine, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, China.
Ann Hematol. 2014 Jul;93(7):1177-83. doi: 10.1007/s00277-014-2024-1. Epub 2014 Mar 6.
Castleman's disease (CD) is a benign lymphoproliferative disorder characterized by dysfunctional lymphatic node hyperplasia. Lymphatic node hyperplasia is associated with elevated levels of inhibitor of differentiation 1 (ID1) in many human tumors. To assess the possible role of ID1 expression as a prognostic marker in multicentric CD (MCD), intra-lymph node ID1 expression was analyzed and related to clinical characteristics and outcomes in 48 patients. Furthermore, the correlation between ID1 and possible signaling molecules such as interleukin-6 (IL6), phosphorylated extracellular response kinase (p-ERK), and vascular endothelial growth factor C (VEGFC) was explored on six fresh MCD surgical specimens. Immunohistochemistry revealed that the patients with extensive ID1 expression had significantly poorer prognosis, compared to those with localized ID1. In addition, ID1 was positively associated with levels of IL6, p-ERK, and VEGFC. We conclude that ID1 may ultimately be a prognostic marker in MCD and that the IL6/ERK/VEGFC pathway is involved in the progress of this disease.
卡斯特曼病（CD）是一种以淋巴结功能失调性增生为特征的良性淋巴增生性疾病。在许多人类肿瘤中，淋巴结增生与分化抑制因子1（ID1）水平升高有关。为了评估ID1表达作为多中心型CD（MCD）预后标志物的潜在作用，分析了48例患者的淋巴结内ID1表达情况，并将其与临床特征及预后相关联。此外，还在6例新鲜的MCD手术标本上探究了ID1与可能的信号分子如白细胞介素-6（IL6）、磷酸化细胞外信号调节激酶（p-ERK）和血管内皮生长因子C（VEGFC）之间的相关性。免疫组织化学显示，与ID1局部表达的患者相比，ID1广泛表达的患者预后明显更差。此外，ID1与IL6、p-ERK和VEGFC水平呈正相关。我们得出结论，ID1最终可能是MCD的预后标志物，且IL6/ERK/VEGFC通路参与了该疾病的进展。
